Regulatory B10 Cells Increase after Rituximab Therapy but Not after Conventional Immunosuppression in Patients with Pemphigus.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Chen, AlanYoshizaki, Ayumi
Miyagaki, Tomomitsu
Streilein, Robert D
Tedder, Thomas F
Hall, Russell P
Date
2021-02Journal
Journal of Investigative DermatologyPublisher
Elsevier B. V.Type
Article
Metadata
Show full item recordIdentifier to cite or link to this item
http://hdl.handle.net/10713/14733ae974a485f413a2113503eed53cd6c53
10.1016/j.jid.2020.06.018
Scopus Count
Collections
Related articles
- Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
- Authors: Snast I, Spitzer L, Hodak E, Levi A, Mimouni D, Leshem YA
- Issue date: 2020 Aug 5
- Decreased level of interleukin-10-producing B cells in patients with pemphigus but not in patients with pemphigoid.
- Authors: Kabuto M, Fujimoto N, Takahashi T, Tanaka T
- Issue date: 2017 May
- Rituximab in the management of juvenile pemphigus foliaceus.
- Authors: Loh TY, Paravar T
- Issue date: 2017 Jun 15
- Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.
- Authors: Feldman RJ, Ahmed AR
- Issue date: 2011 Jul
- Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris.
- Authors: Bhattacharjee R, De D, Handa S, Minz RW, Saikia B, Joshi N
- Issue date: 2016